Sharp Acquires Berkshire Sterile Manufacturing
Purchase allows company to provide a fully integrated small-to-medium scale sterile injectable service offering for the biopharma industry.
Sharp, a provider of commercial pharmaceutical packaging and clinical trial supply services, has acquired Berkshire Sterile Manufacturing (BSM), a fill-finish contract development and manufacturing organization (CDMO) for clinical and commercial sterile injectable products.
The acquisition enables Sharp to now provide a fully integrated small-to-medium scale sterile injectable service offering for the biopharma industry; the company’s existing clinical supply, packaging, and distribution solutions are expected to complement BSM’s sterile manufacturing knowledge.
“The market continues to demand expertise and capacity in sterile manufacturing due in part to the growth in rare and orphan disease therapies,” says Kevin Orfan, Sharp’s president and CEO. “With sterile injectables a huge part of addressing this unmet medical need, the acquisition of BSM allows Sharp to provide a fully integrated solution for our biopharma clients that is a natural extension of our existing injectables and clinical packaging expertise.”
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Multi-Indication Drug Branding in Today’s Pharmaceutical Industry
July 2nd 2025As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.
